April 30, 2024
Via: Camila MendesElon Musk. Jeff Bezos. Bill Gates. These three men have a lot in common. They’re all tech founders who have disrupted their respective industries and cemented their place in the annals of history for their global (and extra-terrestrial) dominance. Between […]
July 13, 2022
Via: Pharmaphorum“Your primary endpoint is now down to a subjective measure in different trial centres, perhaps done by different people with different subjectivity,” says David van Zuydam, CEO of Head Therapeutics. “And now we’re going to determine whether this drug is […]
July 11, 2022
Via: PharmaphorumAbbVie first bought in to the programme with a $205 million upfront payment five years ago, attracted by the potential to use checkpoint inhibitors to try to reproduce in neurology the sometimes stunning results achieved with the class in oncology. […]
Biotech, Cell and Gene Therapy, Industry, News
February 28, 2020
Via: FierceBiotechA year ago, Sangamo’s shares sank after it posted lackluster data for its genome-editing therapy; 12 months down the line, and it’s a complete reversal for the biotech as Biogen lays down a major upfront and biobucks pact for several […]
July 11, 2024
July 11, 2024
July 19, 2024
Copyright © 2024. All rights reserved
